Filing Flows

Filing Flows › Health Care › Viatris (VTRS)

Viatris (VTRS) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Viatris (VTRS) Q3 2026 earnings results →

Q3 2026 Revenue down 0% year over year to $3.7B · 9¢ of every $1 of revenue lost · operating margin 7.0%

Viatris made $3.7B in Q3 2026 (-0.3% Y/Y): Brands $2.5B, Lipitor $452M, EpiPen® Auto-Injectors $156M. Operating margin 7.0%, net loss $325M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$3.7B
Year over year-0.3%
Operating margin7.0%
Net earnings−$325M
Operating cash flow$899M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Viatris Q3 2026 revenue breakdown: Sankey diagram of revenue (Brands, Lipitor, EpiPen® Auto-Injectors, Lyrica ®), costs, profit and cash flow
Viatris Q3 2026 revenue breakdown — free to use with credit and a link (terms). Share on X
Embed this chart on your site

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Revenue was $3.7B in Q3 2026, roughly flat year over year and roughly flat from the previous quarter. Brands was the largest line at 66% of revenue. Influvac ® lost $0.03B year over year (down 28%), 335% of the total change.

Gross margin was 38.4%, up 1.9 points from Q3 2025. Operating profit was $0.26B, a 7.0% margin (up 2.2 points year over year). Operating expenses fell 1% while revenue was flat. The quarter ended with a net loss of $0.33B, wider than the previous quarter's $0.12B loss.

Operating cash flow was $0.90B (up 21% year over year). Non-cash charges added back $0.70B of depreciation and amortization and $0.04B of share-based compensation. Working capital and other items added $0.49B. Capital expenditures of $0.09B left free cash flow of $0.81B.

Quarterly history

Viatris revenue by quarterViatris revenue by quarter$3.3BQ1 2025$3.6BQ2 2025$3.8BQ3 2025$3.5BQ1 2026$3.8BQ2 2026$3.7BQ3 2026
Viatris net earnings by quarterViatris net earnings by quarter−$3.0BQ1 2025−$4.6MQ2 2025−$128MQ3 2025$176MQ1 2026−$119MQ2 2026−$325MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 5, 2026$3.7B-0.3%7.0%−$325M$899M
Q2 202610-QAug 6, 2026$3.8B+5%0.2%−$119M$382M
Q1 202610-QMay 7, 2026$3.5B+8%-2.3%$176M$388M
Q3 202510-QNov 6, 2025$3.8B+0.2%4.8%−$128M$745M
Q2 202510-QAug 7, 2025$3.6B-6%6.5%−$4.6M$220M
Q1 202510-QMay 8, 2025$3.3B-11%-88.6%−$3.0B$536M

Charts

Viatris: revenue growth, year over year and quarter over quarterViatris: revenue growth, year over year and quarter over quarterY/YQ/Q-11%Q1 2025-6%+10%Q2 2025+0%+5%Q3 2025+8%-6%Q1 2026+5%+7%Q2 20260%0%Q3 2026
Latest (Q3 2026): Y/Y 0%, Q/Q 0%.
Viatris: where the cash came from (+) and went (−), TTM to Q3 2026Viatris: where the cash came from (+) and went (−), TTM to Q3 2026Operating cash flow$2.5BNet borrowing (+) / repaid (−)−$924MCash drawn (+) / kept (−)−$789MOther investing$682MPartners−$555MBuybacks−$385MCapital spending−$375MTaxes on employees’ shares−$57.4MOther financing−$53.5MExchange rates−$30.4MShares issued$2.3M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Viatris: profit against cash, quarter by quarterViatris: profit against cash, quarter by quarterNet incomeOperating cash flow−$326M$379MQ2 2024$94.8M$826MQ3 2024−$3.0B$536MQ1 2025−$4.6M$220MQ2 2025−$128M$745MQ3 2025$176M$388MQ1 2026−$119M$382MQ2 2026−$325M$899MQ3 2026
Latest (Q3 2026): Net income −$325M, Operating cash flow $899M.
Viatris: diluted shares by fiscal year (split-adjusted)Viatris: diluted shares by fiscal year (split-adjusted)1.20BFY20201.21BFY20211.22BFY20221.21BFY2023
+0.4% since FY2020: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY2021.
Viatris: long-term debt falling due (FY2025)Viatris: long-term debt falling due (FY2025)$1.7B2027$1.6B2028$254M2029$1.4B2030$7.9BLater
Cash $1.3B, short-term investments $40.7M, long-term debt — at 2025-12-31.
Viatris in its industry: growth against margin (225 companies, SIC 2834)Viatris in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMVTRS (0%, 7%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Viatris

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.

In its own words, from its 10-K, filed Feb 26, 2026.

Viatris against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -0.3% against the peers' median +7%. Operating margin: 7.0% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
VTRS ViatrisQ3 2026$3.7B-0.3%7.0%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Viatris 10-Q on SEC EDGAR · CIK 1792044 · Pharmaceutical Preparations

Guidance and outlook

Viatris: what its forward-looking statements are about (10-Q filed 2026-11-05)Viatris: what its forward-looking statements are about (10-Q filed 2026-11-05)Other5Costs4Supply chain4Demand3People3Deals2Legal & regulation2Financing2Products2Buybacks & dividends2
30 statements; tone -0.07 (−1 all cautious, +1 all confident); 4 hedged.
Viatris: outlook statements against the filing beforeViatris: outlook statements against the filing beforeConfident6Cautious8

13F: who owns VTRS and who is buying

Largest holders of VTRS (13F)Largest holders of VTRS (13F)Vanguard Group$1.7BFMR LLC$1.5BBlackRock$1.4BVanguard Capital Management LLC$1.2BDavis Selected Advisers$1.2BPrice T Rowe Associates$1.1BVanguard Portfolio Management LLC$862MState Street$843MRubric Capital Management LP$543MGeode Capital Management, LLC$520M
Funds' net buying of VTRS by quarter (13F)Funds' net buying of VTRS by quarter (13F)$57.4M2024-09−$10.5M2024-12−$242M2025-03$77.3M2025-06−$74.5M2025-09$222M2025-12$252M2026-03$766M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on VTRS

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare VTRS with

中文版：Viatris（VTRS）财报

Español · Français